Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neuro-oncology

Building Your Care Team and Preparing for Visits

At a Glance

People with diffuse leptomeningeal melanocytosis often need a coordinated team at a rare-disease center. Before the visit, gather original brain and spine scans, biopsy materials, spinal-fluid reports, and complete genetic results so specialists can review the full picture.

Because Diffuse Leptomeningeal Melanocytosis (DLM) and Neurocutaneous Melanosis (NCM) are ultra-rare and complex, they cannot be managed by a single doctor. Success depends on a high-functioning multidisciplinary team—a group of specialists from different fields who collaborate to coordinate your care [1][2].

Establishing this team quickly is a priority. You need a center where these experts can correlate your imaging, pathology, and genetic results into a single, cohesive plan [1][3].

Your Essential Care Team

Each specialist plays a specific, vital role in managing the condition, with distinct pediatric and adult pathways:

  • Neuro-Oncologist: Coordinates the overall treatment plan, evaluates targeted therapies or clinical trials, and oversees the biological management [4][5].
  • Neurosurgeon: Responsible for the physical management of the brain and spine, including performing biopsies, placing shunts, and surgically relieving pressure [6][7].
  • Neurologist / Epileptologist: Focuses on the brain’s electrical health, finding the right antiseizure medications and monitoring EEG activity [7][8].
  • Dermatologist: For those with NCM, a dermatologist monitors congenital melanocytic nevi and watches for any signs of skin melanoma [9][10].
  • Neuro-Radiologist and Neuropathologist: They interpret complex MRIs of the whole brain and spine and examine tissue samples under the microscope to confirm the diagnosis [11][6].
  • Extended Support Team: This includes rehabilitation (PT/OT/speech), neuropsychology, genetic counseling, social work, and palliative care specialists, all crucial for long-term care and quality of life.

Preparing for the First Consultation

When you visit a specialized rare-disease center, organizing your data is vital to ensure the team has what they need [4]. Check with the center to see if images and pathology can be transferred electronically; if not, obtaining the physical items is essential.

The “Must-Have” List for Your Visit:

  1. Imaging on Discs: Ask for the actual DICOM files (the original digital images) on a CD or via a secure portal for every MRI and CT scan [11]. The specialists need to look at the raw images themselves [12].
  2. Pathology Materials: If a biopsy was done, request that the pathology department ship the slides and tissue blocks to the new center for expert confirmation [4][3].
  3. Cerebrospinal Fluid (CSF) Reports: Provide results from lumbar punctures, including cytology and protein levels [13][14].
  4. Genetic Sequencing Results: Bring the full molecular report for any testing of mutations like NRAS, GNAQ, or BRAF [15][16].

Navigating the Logistics

The logistical burden is often overwhelming [17].

  • Ask for a Patient Navigator: Many major centers have navigators who can help coordinate appointments and connect you with resources [18].
  • Check Telehealth Options: Ask if records review or follow-up appointments can be done via telehealth to reduce the burden of travel, especially if you live far from the specialist center [19].

Remember, you are building a long-term partnership. The goal is to ensure that the experts have the data they need to give you the most accurate roadmap possible [20][5].

Common questions in this guide

Which specialists usually care for someone with diffuse leptomeningeal melanocytosis?
A multidisciplinary team may include a neuro-oncologist, neurosurgeon, neurologist or epileptologist, dermatologist when neurocutaneous melanosis is present, neuroradiologist, and neuropathologist. Rehabilitation, neuropsychology, genetic counseling, social work, and palliative care can support long-term needs.
What should I bring to my first DLM specialist appointment?
Bring original DICOM imaging files for all brain and spine MRI or CT scans, pathology slides and tissue blocks if a biopsy was performed, cerebrospinal fluid reports, and complete genetic sequencing results. Confirm with the center whether records can be sent electronically or require physical transfer.
Why do specialists need the original scans and pathology materials?
A rare-disease center may need to review the raw images and tissue rather than rely only on written summaries. Reviewing imaging, pathology, cerebrospinal fluid, and genetic findings together helps the team confirm the diagnosis and plan coordinated care.
What genetic results are useful for a DLM consultation?
Bring the full molecular report for testing that includes mutations such as NRAS, GNAQ, or BRAF, if those tests were performed. The neuro-oncology team may consider these results when evaluating targeted therapies or clinical-trial options.
Can a molecular tumor board help guide treatment for DLM or NCM?
Ask whether the center reviews DLM or NCM cases through a multidisciplinary molecular tumor board. This group can bring oncology, neurosurgery, neurology, radiology, pathology, and genetics perspectives together when discussing targeted therapy or clinical-trial options.
How can I coordinate care if the specialist center is far away?
Ask whether a patient navigator can coordinate appointments and resources, and whether records review or follow-up can be done through telehealth. Keep a central list of team members, their roles, and contact information so urgent questions reach the appropriate specialist.

Get notified when new evidence is published on Diffuse leptomeningeal melanocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    [Clinicopathological features of diffuse leptomeningeal glioneuronal tumor].

    Tu JH, Wang LM, Liu L, et al.

    Zhonghua bing li xue za zhi = Chinese journal of pathology 2021; (50(8)):876-881 doi:10.3760/cma.j.cn112151-20210320-00218.

    PMID: 34344070
  2. 2

    Understanding diffuse leptomeningeal glioneuronal tumors.

    Bajin IY, Levine A, Dewan MC, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2024; (40(8)):2359-2366 doi:10.1007/s00381-024-06432-6.

    PMID: 38795167
  3. 3

    Primary amelanotic leptomeningeal melanocytosis mimicking subarachnoid hemorrhage: a case report of the deceptive masquerader.

    Juan YC, Kuo JS, Chen CC, et al.

    Frontiers in oncology 2026; (16()):1768860 doi:10.3389/fonc.2026.1768860.

    PMID: 42147222
  4. 4

    Review of the Recent Changes in the WHO Classification for Pediatric Brain and Spinal Cord Tumors.

    Halfpenny AM, Wood MD

    Pediatric neurosurgery 2023; (58(5)):337-355 doi:10.1159/000528957.

    PMID: 36617415
  5. 5

    Pearls & Oy-sters: Primary Diffuse Leptomeningeal Melanocytosis: A Diagnostic Conundrum.

    Selvarajan JMP, Epari S, Sahu A, et al.

    Neurology 2023; (101(5)):e576-e580 doi:10.1212/WNL.0000000000207195.

    PMID: 36878703
  6. 6

    Primary Meningeal Melanocytic Tumors of the Central Nervous System: A Review from the Ultra-Rare Brain Tumors Task Force of the European Network for Rare Cancers (EURACAN).

    Pellerino A, Verdijk RM, Nichelli L, et al.

    Cancers 2024; (16(14)) doi:10.3390/cancers16142508.

    PMID: 39061148
  7. 7

    Neurosurgical management of patients with neurocutaneous melanosis: a systematic review.

    Rahman RK, Majmundar N, Ghani H, et al.

    Neurosurgical focus 2022; (52(5)):E8 doi:10.3171/2022.2.FOCUS21791.

    PMID: 35535823
  8. 8

    Shunt Surgery for Neurocutaneous Melanosis with Hydrocephalus: Case Report and Review of the Literature.

    Omar AT, Bagnas MAC, Del Rosario-Blasco KAR, et al.

    World neurosurgery 2018; (120()):583-589.e3 doi:10.1016/j.wneu.2018.09.002.

    PMID: 30205217
  9. 9

    Neurocutaneous melanosis.

    Islam MP

    Handbook of clinical neurology 2015; (132()):111-7.

    PMID: 26564074
  10. 10

    Severe hydrocephalus caused by diffuse leptomeningeal and neurocutaneous melanocytosis of antenatal onset: a clinical, pathologic, and molecular study of 2 cases.

    Uguen A, Laurent C, Samaison L, et al.

    Human pathology 2015; (46(8)):1189-96.

    PMID: 26037215
  11. 11

    Clinical progression, pathological characteristics, and radiological findings in children with diffuse leptomeningeal glioneuronal tumors: A systematic review.

    Jiang H, Qiu L, Song J, et al.

    Frontiers in oncology 2022; (12()):970076 doi:10.3389/fonc.2022.970076.

    PMID: 36185310
  12. 12

    From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review.

    De Carli R, Minichini V, Lebrun L, et al.

    Cancers 2026; (18(4)) doi:10.3390/cancers18040549.

    PMID: 41749803
  13. 13

    Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients.

    Miller AM, Szalontay L, Bouvier N, et al.

    Neuro-oncology 2022; (24(10)):1763-1772 doi:10.1093/neuonc/noac035.

    PMID: 35148412
  14. 14

    A Case of Diffuse Leptomeningeal Glioneuronal Tumor Misdiagnosed as Chronic Tuberculous Meningitis without Brain Biopsy.

    Lee JK, Ko HC, Choi JG, et al.

    Case reports in neurological medicine 2018; (2018()):1391943 doi:10.1155/2018/1391943.

    PMID: 30112228
  15. 15

    Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma.

    Hanft KM, Hamed E, Kaiser M, et al.

    Pediatric blood & cancer 2022; (69(4)):e29468 doi:10.1002/pbc.29468.

    PMID: 34866327
  16. 16

    Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.

    Deng MY, Sill M, Chiang J, et al.

    Acta neuropathologica 2018; (136(2)):239-253 doi:10.1007/s00401-018-1865-4.

    PMID: 29766299
  17. 17

    Information Needs Regarding Cognitive Late Effects of Caregivers of Central Nervous System Tumor Survivors.

    Schuele K, Bennett AE, Varughese T, et al.

    OTJR : occupation, participation and health 2019; (39(3)):159-166 doi:10.1177/1539449218809943.

    PMID: 30417736
  18. 18

    Patient navigation in neuro-oncology: A scoping review of programs supporting patients with CNS tumors.

    Shafeek S, Placide K, Elshiekh C, et al.

    Equity neuroscience 2026; (2(3)):100067 doi:10.1016/j.neuros.2026.100067.

    PMID: 42719432
  19. 19

    Pediatric central nervous system tumor survivor and caregiver experiences with multidisciplinary telehealth.

    Cacciotti C, Chua IS, Cuadra J, et al.

    Journal of neuro-oncology 2023; (162(1)):191-198 doi:10.1007/s11060-023-04281-y.

    PMID: 36890398
  20. 20

    The pivotal role of neurosurgeons in transitional care: A comprehensive tertiary healthcare institution's experience.

    Chew Z, Lim HL, Mahmood S, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2024; (40(12)):4271-4278 doi:10.1007/s00381-024-06638-8.

    PMID: 39367890

This page is for informational purposes only and does not constitute medical advice. It can help you organize a DLM or NCM consultation, but your treating specialists should interpret your records and guide decisions about testing, treatment, and urgent symptoms.

Guide contents Diffuse leptomeningeal melanocytosis
Research & Literature
05 Systemic and Radiation Treatments 07 Prognosis, Monitoring, and the Role of Support